İdiyopatik Santral Erken Ergenlik Tanılı Bir Grup Hastanın Başvuru ve Büyüme Özellikleri

Amaç: Bu çalışmada idiyopatik santral erken ergenlik (SEE) tanılı hastalarda etiyoloji, prognoz, klinik özellikler ve tedavi yanıtı üzerine bir değerlendirme amaçlanmıştır. Yöntem: Çocuk endokrinoloji polikliniğimizde Haziran 2001—Eylül 2015 döneminde idiyopatik SEE tanısı konmuş olan toplam 175 hastanın tıbbi kayıtları geriye dönük olarak incelenmiştir. Bulgular: Hastaların büyük kısmı kız ve 6 yaşından büyük idi. Gonadotropin salgılatıcı hormon analogları ile tedavinin kilo aldırmadığı, erken başvuru ve erken tedavi ile öngörülen boyda artış sağlandığı saptandı. Sonuç: İdiyopatik SEE’li hastalarda erken tanı ve tedavi büyüme potansiyelinin korunmasında önemli bir rol oynamaktadır.

The Admission and Growth Characteristics of a Group of Patients Diagnosed with Idiopathic Central Precocious Puberty

Aim: In this study, we aimed to evaluate the etiology, prognosis, clinical characteristics, and treatment response in patients diagnosed with idiopathic central precocious puberty (CPP). Methods: We retrospectively reviewed the medical records of a total of 175 patients who were diagnosed with idiopathic CPP at our pediatric endocrinology outpatient clinic between June 2001 and September 2015. Results: Most of the patients were girls and older than 6 years of age. We found that treatment with gonadotropin-releasing hormone analogues did not cause weight gain, and that younger age at admission and early treatment resulted in an increase in predicted height. Conclusion: Early diagnosis and treatment play an important role in the preservation of growth potential in patients with idiopathic CPP.

PDF

___

1. Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of the puberty in primates. Endocr Rev. 2001;22:111–51.
2. Wheeler MD. Physical changes of puberty. Endocrinol Metab Clin North Am. 1991;20:1–14.
3. Lee PA, Houk CP. Puberty and its disorders. In: Lifshitz F (ed.), Pediatric Endocrinology, 5. ed. Londra: Informa Healthcare; 2007:272–303.
4. Ebling FJ. The neuroendocrine timing of puberty. Reproduction. 2005;129:675–83.
5. Partsch CJ, Heger S, Sippel WG. Management and outcome central precocious puberty. Clin Endocrinol. 2002;56:129–48.
6. Comite F, Cassoria F, Barnes KM, Hench KD, Dwyer A, Skerda MC, ve ark. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty: long term effect on somatic growth, bone maturation and predicted height. JAMA. 1986;255:2613–6.
7. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long term treatment with doslorelin. J Clin Endocrinol Metab. 1991;73:1235–40.
8. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008;159(ek 1):S3–8.
9. Anasti JN, Flack MR, Froclich J. A potential novel mechanism of precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:276–9.
10. Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol. 1976;3:109–26.
11. Alikaşifoğlu A, Vuralli D, Gonc EN. Changing etiological trends in male precocious puberty: evalution of 100 cases wih central precocious puberty over the last decade. Horm Res Paediatr. 2015;83:340–4.
12. Gaibicani E, Allali S, Durand A, Sommet J, Couto-Silva AC, Brauner R. Presentation of 493 consecutive girls with idiopathic central precocious puberty: a single center study. PloS One. 2013;8(7):e70931.
13. Ibanez L, de Zegher F. Puberty after prenatal growth restraint. Horm Res. 2006;65(ek 3):112–5.
14. Trivin C, Couta-Silva AC, Sainte-Rose C, Chemaitilly W. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol. 2001;54:289–94.
15. Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012;78:304–11.
16. van der Sluis IM, Boot AM, Krenning EP, Drop SLS, Keizer-Schrama SMPFM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin End Met. 2002;87:506–12.
17. Pasquino AM, Pucarelli I, Passeri F, Segni M, Mancini MA, Municchi G. Progression of premature thelarche to central precocious puberty. J Pediatr. 1995;126:11–4.
18. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Human Repr Update. 2004;10(2):135–47.